Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03082729 · ClinicalTrials.gov registry record · Phase 4
Vascular Inflammation in Psoriasis - Apremilast
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT03082729: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT03082729 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03082729, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of the VIP-A study is to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03082729
The ClinicalTrials.gov registry entry for NCT03082729 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT03082729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03082729 about?
NCT03082729 is a clinical study titled "Vascular Inflammation in Psoriasis - Apremilast". The purpose of the VIP-A study is to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis.
What is the current status of trial NCT03082729?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2017-04-24. Estimated completion is 2021-08-17.
What interventions are being tested in trial NCT03082729?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT03082729?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.